All patients reached peak levels of lentiviral copies of CD19/22 CAR T-cells within 2 weeks, which was consistent with previous reports on hematological malignancies receiving CAR T-cell therapy [32, 33]; however, another attractive phenomenon was the undetectable lentiviral copies of CD19/22 CAR T-cells in vivo within a median time of <3 months after infusion. Here, CD19 is linked to hematologic disorder.